Therapeutic agents for adiposity or fatty liver

A technology for the treatment of drugs and fatty liver, applied in drug combination, pharmaceutical formula, digestive system, etc.

Inactive Publication Date: 2008-10-15
殷正丰 +2
View PDF0 Cites 28 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the study of icariin inhibiting the eating and weight loss of mice by inhibiting FAS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic agents for adiposity or fatty liver
  • Therapeutic agents for adiposity or fatty liver
  • Therapeutic agents for adiposity or fatty liver

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Preparation of icariin (see Ye Haiyong et al., Zhejiang University Journal (Medical Science), 2005, 34(2): 131-136)

[0047] Take 2 kg of Epimedium sagittarius collected in the mountains of southern China, grind it into powder, and then extract it with 95% ethanol (10 L). 250 g of concentrated material were obtained, which was then further extracted with 2.5 L of chloroform, ethyl acetate and n-butanol. Pack 8 g of ethyl acetate extract and 10 g of n-butanol extract into a silica gel chromatography column, and wash with CHCl 3 -MeOH-HCOOH (15:1:0.5) and CHCl 3 -MeOH (8:2) eluted separately. Through this process, 300 mg of icariin and noricariin precursor icariin can be obtained. The precursor is then hydrolyzed according to the method briefly described below to obtain icariin. Solution A: 80 mg precursor was sonicated in 18 ml methanol solution; Solution B: 500 U (0.433 g) cellulase was dissolved in 180 ml (0.1 mol / L), pH 5.0 acetate buffer. Solution A was slowly a...

Embodiment 2

[0049] Use (2- 14 C) Inhibitory activity of icariin on cellular fatty acid production determined by acetate incorporation method

[0050] After treating LnCAP cells with different concentrations of icariin for 5 hours or 24 hours, 2- 14 C-labeled acetate (57 mCi / mmol; 2 μCi / dish; Amersham Biosciences) was added to the LnCAP cell culture medium. After incubation for 4 hours, collect the cells and medium, and resuspend the collected cells in 0.8ml PBS. Apply the Bligh Dyer method (Swinnen J.V. et al., Endocrinology 1996; 137:4468-4474) to extract lipids, and quantify the (2- 14 C) Acetate incorporation. The obtained results were normalized to the sample protein content. See the lipogenesis-icariin concentration curve after icariin treatment of LnCAP cells figure 1 .

Embodiment 3

[0052] Inhibition of Icaritin on the Activity of Fatty Acid Synthase in LnCAP Cell Extracts

[0053] The FAS enzyme activity was determined using LnCAP cell protein extracts (Brusselmans K. et al., J Biol Chem. 2005 Feb 18; 280(7): 5636-5645). LnCAP cells were collected by centrifugation, resuspended in hypotonic buffer (1 mM EDTA, 20 mM Tris-HCl, pH 7.5), and then BCA method (Pierce) was used to determine the protein content of the sample. An equal amount of protein (50 μg) and different concentrations of icariin (0.03-30 μm) were placed in 2.5 ml of phosphate buffer (100 mM, pH 7.0), and pre-incubated at 37° C. for 30 minutes. Then add 20 μl reaction solution [2.5mM NADPH, 1.25mM acetyl-CoA, 1.25mM malonyl-CoA, 0.02mM [2- 14 C] Malonyl-CoA (60mCi / mmol; PerkinElmer Life Sciences)], incubate at 37°C for another 15 minutes, add 3ml of ice-cold 1M hydrochloric acid / methanol mixture (6:4, V / V) to terminate the reaction, and wash with petroleum Ether-extracted fatty acids were a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine with icaritin as active component for treating obesity or fatty livers. The pharmacological experiment shows that the icaritin is an effective fatty acid synthetase inhibitor; can inhibit food intake and reduce weight of DIO mice; reduce adipose degeneration of the livers; and reduce the degree of ischemia / reperfusion injuries of the livers with adipose degeneration. The acute toxicity test of the icaritin on the mice shows that the icaritin has no toxicity. Therefore, the icaritin has wide development prospect, and can be used for preparing new drugs for treating obesity or fatty liver.

Description

technical field [0001] The invention relates to a medicine for treating obesity or fatty liver. Background technique [0002] Epimedium is a pungent ornamental herb commonly found in Asia and the Mediterranean region. The Chinese call it Epimedium, which roughly translates to "unbridled goat grass." Epimedium is a genus that includes a variety of related plants, some of which have been used medicinally, including Epimedium sagitta, Epimedium Berberidaceae, Epimedium grandiflora, and Epimedium korean. Epimedium sagittarius is an important traditional Chinese herb widely used as a tonic and antirheumatic in China, Japan, and Korea, and has been shown to be effective in the treatment of osteoporosis, cardiovascular diseases, and tumors. [0003] Icariin (ICA) (molecular weight 676), a flavonol glycoside, is the main constituent of Epimedium sagittarius. Recently, it has been reported that icariin isolated from Epimedium is a potent agonist of neuromedin U2 receptor (NMU2R), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P3/04A61P1/16
Inventor 张南殷正丰邱日辉
Owner 殷正丰
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap